Eckert & Ziegler at a Glance...Rohstoffe/ API Rohstoffe/ API LDR LDR HDR Raw materials API Projects/...

1

Eckert & Ziegler

at a Glance

German Equity Forum

Frankfurt

26 November 2019

Dr. Andreas Eckert

CEO

2

Berlin

Globally Positioned for 25 Years

Niche Player in Isotope Market

Geräte

Rohstoffe/ API

Rohstoffe/ API

LDR

LDR

HDR

Raw materials

API

Projects/

API

Pharmaceuticals

(RADIOPHARMA)

Synthesis

Devices

EUR 80 Mio.

59%

EUR 20 Mio.

16%

EUR 33 Mio.

25%

Strong 3rd Half Year 2019 with Revenues of € 133 Mio. (FY 2018: € 169 Mio.)

Industrial Components

(ISOTOPE PRODUCTS)

Production

Services

Trading

Disposal

Cancer Radiation(RADIATION THERAPY)

Implants

Applicators

Devices

Slides for Illustration – The spoken word shall be binding

3

From January 1st 2020:

Medical Segment Pool

Geräte

Rohstoffe/ API

Rohstoffe/ API

LDR

LDR

HDR

Raw materials

API

Projects/

API

Pharmaceuticals

(RADIOPHARMA)

Synthesis

Devices

Industrial Components

(ISOTOPE PRODUCTS)

Production

Services

Trading

Disposal

Cancer Radiation(RADIATION THERAPY)

Implants

Applicators

Devices

From 1.1.2020: MEDICAL


Engineering

800 Employees (Headcounts)

19 Sites Worldwide

4

Result

Q3-2019(Mio. EUR)

Revenues 133,2

Net Income 18,8

2%

2

44%

41%

9%

6%

EUROPE AMERICA ASIA MIDDLE EAST & AFRICA


Revenues of About

€ 170 Mio. in 2018

in M

io. E

UR

5

Incl. discontinued and continued operations

18% organic growth in 2018

0,13 1 2 4 6 6 8 10

24

33 31 29

36

42

5054

71

101

111116

120117

127

140 138

145

169

0

20

40

60

80

100

120

140

160

180

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018


Revenues per SegmentQ3-2019 vs. Q3-2018, Mio. Euro

6

Total Revenues of 133,2 Mio. EUR in Q3-2019 (Q3-2018: Euro 123,8 Mio.)

+ 8% in Q3-2019


Net Income Q3-2019 vs. Q3-2018 in Mio. EUR

7

Net Income of 18,8 Mio. EUR in Q3-2019 (Q3-2018 :13,0 Mio. EUR)

+ 45% in Q3-2019

Folie nur zur Illustration – es gilt das gesprochene Wort

Balance Sheet as of 30.09.2019, in Mio. EUR

8

• Cash and cash equivalents at period end of 71 Mio. EUR

• Debt Free (except accounted leasing according to IFRS 16)

• Equity Ratio of 53%

Cash 71 Equity 131

Recievables 25 Minority Interests 6

Inventory 31 Loans 18

Intangible Assets 70 Accruals/Provisions 66

Fixed Assets 38 Other Short Term Payables 31

Others 25 Other Long Term Payables 6

Total Activ 259 Total Passiv 259


Cashflow in Q3-2019,

in Mio. EUR

9

EBITDA of 36,6 Mio. EUR


Net Liquidity in Q3-2019,in Mio. EUR

10

+10 mm EUR for

treasury shares


2014 2015 2016 2017 2018 Q3-2019

Liquidity 22 31 37 58 54 71

Debt 19 16 12 2 0 0

Net Liquidity 3 15 25 56 54 71

0

10

20

30

40

50

60

70

80

0

10

20

30

40

50

60

70

80

In M

io. E

UR

Share Performance and

Dividend in EUR/Share

11

0,60 0,60 0,600,66

0,8

1,2

0,50

0,60

0,70

0,80

0,90

1,00

1,10

1,20

0

20

40

60

80

100

120

140

160

180

2014 2015 2016 2017 2018 2019

Dividende in EUR / Aktie EUR/Aktie


Overview

12

•Theranostics

•Interventional Radiology

• Outlook

Strategy / Growth Opportunities

13

About tigers, dragons, and other creatures

Our Topics

14

• Poor man‘s PET – Theranostics

• Dying decently – Interventional Radiology

Poor Man‘s PET: Capital Expen-

ditures Become Consumables

• A vision comes true

• Eckert & Ziegler pionieers first pharmaceutically approved

gallium generator worldwide

• No need for CAPEX an expensive cyclotron

• Transfer of an investment into consumables15

Purchase costs incl. Radiopharmacy

6 bis 8 Mio. EUR plus staff

Complex Supply Chains

Become Obsolete

Own Cyclotrons

•Berlin-Adlershof

•Bonn

•Vienna (Seibersdorf)

•new: Warsaw

Exklusive Distribution

•Karlsruhe

•Bad Berka

16

Folie nur zur Illustration – es gilt das gesprochene Wort

Global Market Entrance

of the Generator

• Opens up precision oncology for the bulk of hospitals

• Makes the treatment of niche indications in smaller

clinics more attractive

Slides only for illustration – the spoken word shall be binding 17

Precision Oncology

Still at the Beginning

Advantage

• Therapy only for patientswho respond to thediagnostic

– saves unnecessaryexpenses

– saves unnecessary

patient stress

• Strengthens nuclear physicians as a distribution channel

18

Neuroendocrine tumors

Prostate,

Renal cancer

Non-Hodgkin-Lymphoma

Gastro

THERAPY (Lu-177)DIAGNOSIS (Ge-68)


But: Expansion of Indication

is Likely to Come

19 https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply

Clinical studies with Lu-177 acc. to FDA,

Phase II or higher, as of May 2019


https://clinicaltrials.gov/ct2/results?term=lutetium&age_v=&gndr=&type=&rslt=&phase=1&phase=2&Search=Apply

Number of Diagnoses Could

Suddenly Increase

• Diagnosis is key to therapy details

• Retreatment likely

– Diagnosis and therapy control may add up to ø 2 scans/ patient?

20

https://www.itnonline.com/content/theragnostics-reports-positive-clinical-trial-results-prostate-cancer-study

https://www.itnonline.com/content/theragnostics-reports-positive-clinical-trial-results-prostate-cancer-study

INTERVENTIONAL

RADIOLOGY

Dying decently

Slides only for illustration – the spoken word shall be binding 21

Principle of Inverted Tree

Pellets/spheres are proprietary

Radioactive loading done by Eckert & Ziegler

Huge Number of Cases in China

Attractive Reimbursement

23

Age-standardized incidence rates of hepatocellular carcinoma per 100,000 populations at

risk, in different regions of world (Source: GLOBOCAN 2002).

China

280,000 men

100,000 women

~380,000 cases

per year (!)

Reimbursement China

~ 11,000 US$/ patient


Numerous Medical Device Companies

Start their own Programs

and much more….


Fitting Well into the Picture

• Bayer/ ALGETA– (2014)

• IPSEN/ OPS– 2015

• NOVARTIS/ AAA– (2017)

• NOVARTIS/ Endocyte– 2017

• GCP/ SIRTEX– June 2018

• Boston Scientific/ BTG– November 2018

• Bracco/ Blue Earth – April 2019

2,1 Mrd. USD

2,1 Mrd. USD

4,0 Mrd. USD

0,1 Mrd. USD

Ra-223

Lu-177

1,4 Mrd. USD

Ge-68

Y-90

Ge-68

Y-90 4,2 Mrd. USD

0,5 Mrd. EURF-18

Isotop


M&A Activities

Full Speed Ahead in 2019 as Well

• Bayer/ ALGETA– (2014)

• IPSEN/ OPS– 2015

• NOVARTIS/ AAA– (2017)

• NOVARTIS/ Endocyte– 2017

• GCP/ SIRTEX– Juni 2018

• Boston Scientific/ BTG– November 2018

• Bracco/ Blue Earth – April 2019

2,1 Mrd. USD

2,1 Mrd. USD

4,0 Mrd. USD

0,1 Mrd. USD

Ra-223

Lu-177

1,4 Mrd. USD

Ge-68

Y-90

Ge-68

Y-90 4,2 Mrd. USD

0,5 Mrd. EURF-18

Isotop


Thank you!

27 Slides for Illustration – The spoken word shall be binding

Financial Calendar / IR-Contact

ISIN DE0005659700

Reuters EUZ.DE

28

31.03.2020 Publication FY2019

12.05.2020 Quarterly Report I

May 2020 Spring Conference in Frankfurt

17.06.2020 Annual General Meeting in Berlin

13.08.2020 Quarterly Report II

10.11.2020 Quarterly Report III

Eckert & Ziegler AG

Karolin Riehle

Investor Relations & PR

Robert-Rössle-Str. 10

D-13125 Berlin

Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112

[email protected]

www.ezag.com


Eckert & Ziegler at a Glance...Rohstoffe/ API Rohstoffe/ API LDR LDR HDR Raw materials API Projects/...

Documents

Transcript of Eckert & Ziegler at a Glance...Rohstoffe/ API Rohstoffe/ API LDR LDR HDR Raw materials API Projects/...